CHRU de Montpellier - Hôpital Gui de Chauliac

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.	CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis	Recruiting	Phase 3	2026-02-02		NCT05758831
Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke / TIA	brain disorder, brain ischemia, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, nervous system disorder, stroke disorder, transient ischemic attack, vascular disorder	Recruiting	Not applicable	2025-03-10		NCT02662751

Clinical trials